Skip to main content

Table 1 Patient characteristics according to TP53 status

From: WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma

Variable TP53wild-type TP53mutant p-value
N 261/314 (83.1%) 53/314 (16.9%)  
Age (median, range) 9.0 (5.0 – 18.5) 10.0 (5.0 – 17.0) p = 0.4
Gender (male) 154/261 (59%) 25/53 (47.2%) p = 0.1
Histology    
LCA 31/261 (11.9%) 23/53 (43.4%) p = 0.0001*
Classic 204/261 (78.2%) 25/53 (47.1%)  
Desmoplastic/nodular 21/261 (8.0%) 2/53 (3.8%)  
Missing 5 /261 (1.9%) 3/53 (5.7%)  
M+ disease 80/261 (30.7%) 7/53 (13.2%) p = 0.01
Subgroups    
WNT 72/261 (27.6%) 15/53 (28.3%) p = 0.003**
SHH 59/261 (22.6%) 36/53 (67.9%)  
Group 3 37/261 (14.2%) 0/53 (0%)  
Group 4 92/261 (35.2%) 1/53 (1.9%)  
Missing 1/261 (0.4%) 1/53 (1.9%)  
Death 54/261 (20.7%) 24/53 (45.3%)  
WNT 5/72 (6.9%) 0/15 (0%) p = 0.004***
SHH 9/59 (15.3%) 24/36 (66.7%)  
  1. *Incidence of LCA histological variant in TP53 wild-type and TP53 mutant patients; **Incidence of TP53 mutations in WNT and SHH patients; ***Incidence of death in TP53 mutant population in WNT and SHH patients.